Faculty Candidate Seminar Announcement
  • FENS
  • Faculty Candidate Seminar Announcement

You are here




Molecular Biology Genetics and Bioengineering - Faculty Candidate

Identifying diagnostic biomarkers and therapeutic targets using integrative, adaptive multi-level omics approach 

Rifat Hamoudi


Cancer is heterogeneous disease that is generally initiated through inflammatory pathways and targets many pathways for its progression and metastasis. Current therapeutic approaches involves targeting one molecule in a particular pathway and generally this tend to be a mutation for example Zelboraf targeting BRAF V600E mutation. This approach had limited success resulting in slight survival advantage.

Heterogeneity in diseases is a result of clonal evolution and is an effective strategy for

survival of tumour clones. Identifying key pathways involved in disease development and progression is crucial in identifying key diagnostic biomarkers and therapeutic targets. The genomics field has gone through tremendous leap since the advent of digital pathology and Next Generation Sequencing in 2005, however most of the efforts have focused on sequencing the DNA looking for mutational profiling, CNV and SNPs. This approach was useful in identifying key molecules in a pathway such as MAPK e.g. BRAF V600E mutation, but has not been successful in translating the findings to diagnosing and treating disease. Transcriptomics has shown to be closely correlated to phenotype and epigenetics has elucidated environmental links to DNA changes.

This talk will focus on the use of integrative, adaptive genomic, transcriptomic and epigenetics in identifying key differentially diagnostics biomarkers and how novel ways of analysing transcriptomic data can lead to identifying key therapeutic targets. The talk will also introduce the concept of energy based therapy as an alternative to chemotherapy and show how combining targeted energy based therapeutics can lead to more effective way to treating and managing diseases such as cancer with potential application to other diseases such as diabetes and cardiovascular disease.


Dr. Rifat Hamoudi, BSc, MSc, PhD is a multidisciplinary researcher. He started out as electronic engineer but moved into medical sciences. He has BSc in Biology and Chemistry, Three different MSc degrees from University of London in Engineering, Computer Science and Biochemistry and a PhD from Cambridge University in Molecular Medicine and Pathology.

He worked in cancer genetics at the Royal Marsden Hospital and Institute of Cancer Research and was a member of the team that discovered BRCA2. Following the publishing of the human genome in 2001 he moved to work in molecular pathology establishing and applying novel wet methodologies, algorithms and software for molecular screening and personalised medicine,

diagnostic and prognostic biomarker discoveries and understanding the molecular mechanism of various diseases with a view to identifying key therapeutic targets. More recently, he has used therapeutic targets in photo and sonodynamic therapy to address the problems of heterogeneity and clonal evolution in disease.

He has co-initiated the Personal Genome Project - UK with Professor Stephan Beck and is the lead in software and algorithms development and has written many information management system software using various software engineering methodologies to collate, store clinicopathology information and correlate that to genomics data.

 Dr. Hamoudi is a Fellow of the Institute of Biomedical Sciences, Biological Society, British Computer Society, Institute of Physics and Engineering in Medicine. He has Chartered Engineer and European Engineer status. He has more than 100 publications in high impact journals including PNAS, Nature,

Nature Genetics, Science and Cell in areas including bioinformatics, cancer genetics and molecular pathology. He is in the editorial board of the Journal of Clinical and Medical Imaging and Journal of Translational Oncogenomics.

Currently, he is Associate Professor in Computational & Molecular Pathology and Group Leader in Advanced Targeted Therapeutics at the Research Department of Tissue and Energy within the Division of Surgery & Interventional Sciences at University College London.

January 11, 2016 – 13:40, FENS L048